Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis.

摘要: The primary objective of this study was to determine the incidence rate pathological complete responses (pCRs) following neoadjuvant systemic chemotherapy for treatment peritoneal carcinomatosis (PC) colorectal origin. secondary evaluate whether response assessments predict survival patients treated with curative intent by cytoreductive surgery (CRS). A retrospective review performed 115 who underwent preoperative irinotecan- or oxaliplatin-based chemotherapy, followed 124 procedures CRS alone combined hyperthermic intraperitoneal (HIPEC). defined as mean percentage cancer cells remaining within all specimens. Univariate and multivariate analyses were identify predictors outcome. Twelve (9.7 %) resulted in pCRs, no residual specimens, 25 (20.2 %) major (1 49 % cells), 87 (70.1 %) minor (>50 % cells). cumulative 5-year rates 75 57 % pCR responses, respectively. Using analysis, only independent predictor (P = 0.01; response: hazard ratio [HR] = 4.91; HR = 13.46). No significant identified. Pathological can be achieved PC degree assessed represented a new outcome prognosis intent.